Baxter International Inc. · NYSE:BAX
Baxter International — Raymond James & Associates' 46th Annual Institutional Investors Conference (March 2025)
14 slides from Baxter International's conference presentation, Mar 3, 2025
Slide 1: Raymond James & Associates' 46th Annual Institutional Investors Conference
RAYMOND JAMES & ASSOCIATES’ 46 TH ANNUAL INSTITUTIONAL INVESTORS CONFERENCE Joel Grade Executive Vice President & Chief Financial Officer MARCH 3, 2025 1
Slide 2: Safe Harbor Statement
S A F E H A R B O R S TAT E M E N T This presentation includes forward-looking statements concerning the company’s financial results (including the outlook for first-quarter and full-year 2025) and business development and regulatory activities. These forward-looking statements are based on assumpti
Slide 3: Non-GAAP Financial Measures
NON-GAAP FINANCIAL MEASURES This presentation contains certain forward-looking financial measures that are not calculated in accordance with U.S. GAAP (Generally Accepted Accounting Principles). The forward-looking non-GAAP financial measures include forward-looking adjusted operating margin guidanc
Slide 4: Unwavering in our mission of saving and sustaining lives
U N WAV E R I N G I N O U R MISSION OF S AV I N G A N D S U S TA I N I N G L I V E S 4
Slide 5: Business Highlights
B U S I N E S S H I G H L I G H T S 1,2 Executing broad strategic transformation to enhance performance, accelerate innovation and drive incremental value for all stakeholders Benefitting from balanced and diversified portfolio to deliver results and advance our Mission Completed the sale of the Kid
Slide 6: Strategic Actions to Deliver Enhanced Shareholder Value
S T R AT E G I C A C T I O N S T O D E L I V E R E N H A N C E D S H A R E H O L D E R VA L U E NOW COMPLETE Complete Complete Complete • Finalized operating model • Completed the divestiture • Completed the sale of the and in Q3 2023 began of the BioPharma Solutions Kidney Care business, now report
Slide 7: New Baxter: Increased Agility, Clearer Focus and Better Positioned to Invest
N E W B A X T E R : I N C R E A S E D A G I L I T Y, C L E A R E R F O C U S A N D B E T T E R P O S I T I O N E D T O I N V E S T F O R G R O W T H A N D I N N O VAT I O N Medical Products & Therapies Healthcare Systems & Technologies Pharmaceuticals An essential healthcare partner with an unmatche
Slide 8: Medical Products & Therapies
MEDICAL PRODUCTS & THERAPIES1 Current Portfolio Near Term Launches2 Future Launches Novum IQ LVP & Syringe Infusion IQ Guardian (Digital) OUS3 Novum IQ LVP Platform (Canada / U.S.) Gravity Artificial Intelligence Novum PCA Developed Software to Rest of World U.S. & Set Launches QuickStay Help Identi
Slide 9: Healthcare Systems & Technologies
H E A LT H C A R E S Y S T E M S & T E C H N O L O G I E S 1 Current Portfolio Near Term Launches2 Future Launches Helion Handsfree OR Integration Communication Connected Enhancements System Overhead Lift Voalte Helux Pro System TS7000 Care & Robotic Table Nurse Call Surgical Precision Robotic Med S
Slide 10: Pharmaceuticals
PHARMACEUTICALS1 Current Portfolio Near Term Launches2 Future Launches Targeting ~10 new Injectables & Doxil Zosyn Sevoflurane Vasopressin Vancomycin Norepinephrine product launches Anesthesia per year Cyclophosphamide Daptomycin Ifosfamide Myxredlin Micafungin Ropivicaine Injection Drug Focused on
Slide 11: Strategic Transformation Designed to Create a More Streamlined, Agile Company
S T R AT E G I C T R A N S F O R M AT I O N D E S I G N E D T O C R E AT E A M O R E S T R E A M L I N E D , A G I L E C O M PA N Y F O C U S E D O N E N H A N C I N G VA L U E 1 , 2 • Targeting 4% - 5% operational sales growth annually • Driving sales growth faster than market through innovation an
Slide 12: Baxter (CO) Operating Income Bridge
B A X T E R ( C O ) O P E R AT I N G I N C O M E B R I D G E 1 , 2 , 3 ~100 bps ~40 bps ~185 bps ~(60) bps ~225 bps ~(40) bps4 ~16.5% 13.9% Includes ~225 bps impact from stranded costs FY 2024 Net Benefit from TSA5 Hurricane Operational MSA5 Impact FY 2025 Adjusted and Cost Containment Helene Impact
Slide 13: Continuing Momentum In and Beyond 2025
C O N T I N U I N G M O M E N T U M I N 2 0 2 5 A N D B E YO N D Building on underlying 2024 business momentum and financial progress Assessing potential opportunities to exit select product and/or markets to further optimize portfolio and enhance performance Continuing to drive benefits from vertic
Slide 14: Raymond James & Associates' 46th Annual Institutional Investors Conference
RAYMOND JAMES & ASSOCIATES’ 46 TH ANNUAL INSTITUTIONAL INVESTORS CONFERENCE Joel Grade Executive Vice President & Chief Financial Officer MARCH 3, 2025 14